OKYO Pharma Ltd. (OKYO) is scheduled to present an update on the development of its lead drug candidate, Urcosimod, for the treatment of neuropathic corneal pain at the BIO International Convention, taking place from June 16 to 19, 2025.
Neuropathic corneal pain is a condition that causes severe pain and sensitivity of the eyes, face, or head. The exact cause of neuropathic corneal pain is unknown, but it is thought to result from nerve damage to the cornea combined with inflammation. Currently, there are no FDA-approved drugs to treat this condition.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.